This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Top Research Reports for NVIDIA, Netflix & Merck
by Mark Vickery
New research highlights NVIDIA's AI-driven growth, Netflix's ad-tier momentum and Merck's pipeline progress, while microcaps also make the cut.
MRKPositive Net Change NFLXPositive Net Change MDTPositive Net Change UBSPositive Net Change NVDAPositive Net Change CPIXPositive Net Change SCCOPositive Net Change MCEMNegative Net Change
construction consumer-discretionary medical pharmaceuticals semiconductor
Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates
by Zacks Equity Research
VTRS scores four regulatory wins in 2025, from FDA approval of a generic Sandostatin LAR to NDA and IND clearances across its pipeline.
FOLDPositive Net Change ANIPPositive Net Change CRMDPositive Net Change VTRSNegative Net Change
biotechnology medical pharmaceuticals
Pharma's $370B Bet on America: The ETF Plays for 2026
by Aparajita Dutta
Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.
GSKPositive Net Change ABTPositive Net Change NVSPositive Net Change JNJNegative Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change ABBVPositive Net Change PJPPositive Net Change IHEPositive Net Change PPHPositive Net Change
etfs pharmaceuticals
Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock
by Kinjel Shah
Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.
AZNPositive Net Change PFEPositive Net Change LLYPositive Net Change ABBVPositive Net Change
pharmaceuticals
Can Merck Successfully Steer Through the Upcoming Headwinds?
by Kanishka Das
MRK faces looming Keytruda LOE, falling Gardasil sales and pricing pressure, but new products, pipeline and planned cost savings aim to offset the headwinds.
AZNPositive Net Change RHHBYPositive Net Change BMYPositive Net Change MRKPositive Net Change
pharmaceuticals
Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema
by Zacks Equity Research
NVO files an NDA with the FDA for once-weekly CagriSema, a combo obesity injection showing superior weight loss in obese patients in phase III studies.
NVOPositive Net Change LLYPositive Net Change CRMDPositive Net Change CSTLNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will GILD's Strong HIV Portfolio Reap Rewards in 2026?
by Ekta Bagri
GILD???s HIV franchise gains momentum as twice-yearly PrEP Yeztugo wins FDA approval and late-stage data back a new single-tablet regimen.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant
by Zacks Equity Research
JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.
AZNPositive Net Change JNJNegative Net Change HALOPositive Net Change
biotechs medical pharmaceuticals
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
by Kinjel Shah
J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.
JNJNegative Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change ABBVPositive Net Change FHTXPositive Net Change IBRXNegative Net Change
cancer pharmaceuticals
3 Momentum Stocks That Could Continue Their Strong Run in 2026
by Harendra Ray
AI and healthcare momentum remain strong heading into 2026. NVDA, AVGO and LLY stand out as high-growth leaders with earnings power still driving their rallies.
LLYPositive Net Change NVDAPositive Net Change AVGOPositive Net Change
artificial-intelligence pharmaceuticals
Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share?
by Ahan Chakraborty
NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S. momentum.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi
by Zacks Equity Research
INCY wins EC approval expanding Minjuvi's label, adding a new indication for relapsed or refractory follicular lymphoma after prior therapy.
NVSPositive Net Change QGENPositive Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
by Zacks Equity Research
Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.
RHHBYPositive Net Change CRMDPositive Net Change PCSANegative Net Change CSTLNegative Net Change
biotechnology biotechs medical pharmaceuticals
Best Value Stocks to Buy for Dec. 18
by Zacks Equity Research
KE, COLL and JRVR made it to the Zacks Rank #1 (Strong Buy) value stocks list on Dec. 18, 2025.
JRVRNegative Net Change COLLNegative Net Change KEPositive Net Change
pharmaceuticals
5 Biotech Stocks to Watch for Potential Upside
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector.
ARQTPositive Net Change FOLDPositive Net Change PCRXPositive Net Change ANIPPositive Net Change TNGXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?
by Sundeep Ganoria
PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change SMMTPositive Net Change
biotechs medical pharmaceuticals vaccines
RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know
by Zacks Equity Research
Rezolute shares collapse 79% so far in December after a phase III hyperinsulinism study of its only pipeline candidate miss primary and key secondary endpoints.
ANIPPositive Net Change CRMDPositive Net Change RZLTNegative Net Change CSTLNegative Net Change
biotechnology biotechs medical pharmaceuticals
SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
by Zacks Equity Research
Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib, and a phase III study fails to hit its primary endpoint.
SNYPositive Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechs medical pharmaceuticals
KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data
by Zacks Equity Research
Kyverna Therapeutics shares jump 23% after a registrational phase II study of miv-cel meets primary and all secondary efficacy goals for treating stiff person syndrome.
ANIPPositive Net Change CRMDPositive Net Change CSTLNegative Net Change KYTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike
by Zacks Equity Research
CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.
MRNAPositive Net Change ANIPPositive Net Change CRMDPositive Net Change CSTLNegative Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Eli Lilly or Merck: Where Should Investors Put Their Money?
by Kinjel Shah
LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.
NVOPositive Net Change MRKPositive Net Change LLYPositive Net Change CDTXPositive Net Change
pharmaceuticals
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
by Kinjel Shah
MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward opportunities for bold investors
CELCPositive Net Change OCGNNegative Net Change KROSPositive Net Change MNMDPositive Net Change KYTXPositive Net Change
pharmaceuticals
How AbbVie's Pipeline Is Lining Up Key Product Launches
by Sundeep Ganoria
ABBV is lining up multiple late-stage launches, from Rinvoq label expansions to Parkinson???s and oncology assets nearing FDA decisions.
JNJNegative Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal
by Zacks Equity Research
Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.
GSKPositive Net Change GILDPositive Net Change FOLDPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Top Research Reports for Microsoft, Novartis & RTX
by Mark Vickery
Microsoft, Novartis and RTX headline Zacks' top research picks, spotlighting cloud, pharma innovation and defense demand shaping market leaders.
RYAAYPositive Net Change NVSPositive Net Change MSFTPositive Net Change JCIPositive Net Change VLOPositive Net Change AIRTNegative Net Change RTXPositive Net Change
aerospace computers pharmaceuticals transportation